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Abstract
Background: Platelet-derived chemokines are implicated in several aspects of vascular biology. However, for the chemokine
platelet factor 4 variant (PF-4var/CXCL4L1), released by platelets during thrombosis and with different properties as
compared to PF-4/CXCL4, its role in heart disease is not yet studied. We evaluated the determinants and prognostic value of
the platelet-derived chemokines PF-4var, PF-4 and RANTES/CCL5 in patients with stable coronary artery disease (CAD).
Methodology/Principal Findings: From 205 consecutive patients with stable CAD and preserved left ventricular (LV)
function, blood samples were taken at inclusion and were analyzed for PF-4var, RANTES, platelet factor-4 and N-terminal
pro-B-type natriuretic peptide (NT-proBNP). Patients were followed (median follow-up 2.5 years) for the combined endpoint
of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure. Independent determinants
of PF-4var levels (median 10 ng/ml; interquartile range 8–16 ng/ml) were age, gender and circulating platelet number.
Patients who experienced cardiac events (n=20) during follow-up showed lower levels of PF-4var (8.5 [5.3–10] ng/ml versus
12 [8–16] ng/ml, p=0.033). ROC analysis for events showed an area under the curve (AUC) of 0.82 (95% CI 0.73–0.90,
p,0.001) for higher NT-proBNP levels and an AUC of 0.32 (95% CI 0.19–0.45, p=0.009) for lower PF-4var levels. Cox
proportional hazard analysis showed that PF-4var has an independent prognostic value on top of NT-proBNP.
Conclusions: We conclude that low PF-4var/CXCL4L1 levels are associated with a poor outcome in patients with stable CAD
and preserved LV function. This prognostic value is independent of NT-proBNP levels, suggesting that both neurohormonal
and platelet-related factors determine outcome in these patients.
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Introduction
Platelet factor 4 (PF-4/CXCL4), the first discovered chemokine,
is selectively released from stimulated platelets and has rather
atypical biological properties since it is only a weak leukocyte
chemoattractant compared to other chemokines. However, PF-4 is
reportedly implicated in many biological processes, such as
inhibition of hematopoiesis, platelet coagulation, and activation
of various myeloid and lymphoid leukocyte types [1].
A striking activity of PF-4, shared with its more recently
identified non-allelic variant PF-4var, is the inhibition of en-
dothelial cell proliferation and migration [2,3]. Angiogenesis
induced by angiogenic chemokines (e.g. interleukin-8 (IL-8)/
CXCL8), fibroblast growth factor (FGF) or vascular endothelial
growth factor (VEGF) is significantly reduced by PF-4var and PF-
4. In particular, PF-4var was found to be a more potent angiostatic
chemokine than PF-4 with stronger antitumoral activity in various
animal models [4].
The molecular mechanism by which PF-4 and PF-4var exert
their various biological functions remains an enigma. Classical
chemokines, such as IL-8/CXCL8, predominantly act through
interaction with their high-affinity G protein-coupled receptors
(CXCR1 and CXCR2 for IL-8/CXCL8) [5–7]. In addition to
signaling via CXCR3 [8,9], PF-4 also binds with high affinity to
glycosaminoglycans [10] and forms heterodimers with classical
growth factors, such as FGF-2 and other chemokines [11], such as
RANTES/CCL5 [12]. Remarkably, PF-4var shows lower affinity
for glycosaminoglycans, but shares with PF-4 the chemokine
receptor CXCR3, which is also used by other angiostatic
chemokines, such as interferon-induced protein-10 (IP-10/
CXCL10) [13,14]. However, these interferon-induced CXCR3
ligands are potent chemoattractants for Th1 lymphocytes and
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31343natural killer cells, whereas PF-4var rather attracts immature
dendritic cells [13,14].
Platelet-derived chemokines, including PF-4, are also implicated
in several aspects of vascular biology [1,15], such as monocyte
arrest on endothelial cells (in cooperation with RANTES),
induction of atherosclerotic lesions [12], promotion of thrombosis
[3] and heparin-induced thrombocytopenia [16]. The role of PF-
4var in processes related to atherosclerosis has, however, not yet
been investigated. Therefore, the aim of the present study was to
evaluate the determinants and prognostic significance of PF-4var
in patients with coronary artery disease (CAD). Moreover, we
compared its prognostic value to that of PF-4 and NT-proBNP, a
well validated prognostic marker in patients with stable CAD [17].
Methods
Study populations
In order to obtain normal values for PF-4var, we evaluated 47
normal subjects. These individuals had no history of cardiovas-
cular disease or diabetes, had no cardiac complaints and showed
normal findings on a resting ECG and echocardiogram.
For the CAD patients, we prospectively evaluated 205
consecutive patients with stable CAD. The following clinical
observations were considered as criteria for CAD: previous history
(.6 months) of acute myocardial infarction (AMI), percutaneous
coronary intervention (PCI), coronary artery bypass grafting
(CABG), or documented CAD on coronary angiography (.70%
stenosis). Patients with crescendo angina or angina at rest were
excluded, as well as patients with recent (,6 months) acute
coronary syndromes or cardiac revascularizations [18].
After overnight fasting, patients underwent a study protocol
including venous blood sampling, echocardiography and evalua-
tion of six-minutes walking distance. Echocardiography was
performed with a VIVID-7 scanner (GE Vingmed Ultrasound,
Horten, Norway). The left ventricular ejection fraction (LVEF)
was measured in all patients using Simpson’s method of discs.
Patients with a LVEF$50% were included in the present study. A
six-minutes walking distance test was performed as measurement
of exercise capacity. Routine blood measurements (blood cell
count, creatinine) were performed according to an ISO 17025
Beltest accreditation.
Laboratory measurements
Serum concentration of NT-proBNP was measured on an
Elecsys 2010 apparatus (Roche Diagnostics, Mannheim, Ger-
many) with an automated electrochemiluminescence sandwich
immunoassay. Soluble tumour necrosis factor receptors I and II
(sTNFRI and II) were measured as parameters of inflammation by
ELISA (BioSource, Nivelles, Belgium) with sensitivities of 0.05 and
0.1 ng/ml, respectively.
The CC chemokine RANTES was measured using the ELISA
antibody pair distributed by R&D Systems (Abingdon, UK),
whereas sandwich ELISAs for the CXC chemokines PF-4 and PF-
4var were developed as described [19]. Antibodies against PF-4
and PF-4var were raised in rabbits and purified by protein G
chromatography. Natural PF-4 and recombinant PF-4var, purified
to homogeneity in our laboratory, were used as standards. The PF-
4var ELISA was specific in that PF-4 was not detectable, whereas
the PF-4 ELISA measured both PF-4 and PF-4var [19].
Follow-up
Patients were followed thereafter for the combined primary
outcome measure of death due to cardiovascular causes, non-fatal
myocardial infarction, non-fatal stroke or hospitalization for
congestive heart failure. As secondary outcome measure the
combination of MACE (death due to cardiovascular causes, non-
fatal myocardial infarction, percutaneous coronary intervention
or coronary artery bypass grafting) or hospitalization for con-
gestive heart failure was evaluated. No patient was lost during the
follow-up.
Ethics
This study protocol was approved by the ethical committee of
the Ghent University Hospital (Belgium) and all patients gave
informed consent. The clinical investigations were conducted
according to the principles of the declaration of Helsinki.
Statistical analysis
Statistical analysis was performed using SPSS v 17.0 for
Windows (SPSS Inc., 2008, Chicago, IL, USA). All continuous
variables were tested for normality and log-transformed when
skewed distributions were demonstrated. These are presented as
mean 6 standard deviation or median and interquartile range
when appropriate. Differences between groups were analysed
using ANOVA or Wilcoxon for continuous variables and chi-
square for categorical variables. Spearman correlations were used
to test the association of continuous variables with levels of PF-
4var. Linear regression analysis was used to evaluate independent
predictors of PF-4var levels.
For outcome analysis, multivariate analysis was performed using
Cox proportional hazards models incorporating factors with
predictive significance on univariate analysis and ROC analysis
and hypothesized important factors.
Three models were constructed:
– Model 1 clinical parameters (including age, gender, diabetes,
creatinine, ejection fraction, treatment with betablockers,
statins, antiplatelet drugs and ACE/ARB) with the addition
of NT-proBNP.
– Model 2 included the same clinical parameters as model 1, with
the addition of PF-4var.
– Model 3 included the same clinical parameters as model 1 with
addition of NT-proBNP and PF-4var.
Cumulative event-free survival rates as a function over time
were obtained by the Kaplan-Meier method. Differences in
survival were analyzed by log-rank testing. Event rates per patient
year follow-up were calculated.
For all analyses the level of significance (p) was set at 0.05.
Results
PF-4var levels and determinants in healthy control
subjects
Mean age of the normal subjects was 63611 years (range 28–79
years) and 26 were men (55%). Mean LVEF was 6367%, mean
NT-proBNP 102683 pg/ml and mean creatinine 0.8960.17 mg/
dl. Hypertension was present in 19 individuals (40%) which
required treatment with ACE inhibitors or ARB in 9 (19%), beta-
blockers in 10 (21%), diuretics in 8 (17%) and calcium antagonists
in 5 subjects (11%). Statins were used in 10 (21%) and aspirine in
13 individuals (28%).
Mean value of PF-4var was 14.567.3 (range 5–33) without
significant differences between men and women (13.567.4 vs
15.867.1, p=0.19). No significant correlations were documented
between PF-4var levels and age, body mass index, LVEF,
creatinine and circulating platelets. Only a weak correlation was
present between PF-4var and NT-proBNP (r=20.31, p=0.04).
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subjects with and without hypertension (13.966.7 vs 15.267.9,
p=0.55) or aspirine use (16.268.2 vs 13.966.9, p=0.37).
Clinical characteristics of the population of CAD patients
The clinical and laboratory characteristics of the population of
CAD patients and of the subgroups according to the median PF-
4var value of 10 ng/ml are shown in Table 1. Patients with lower
PF-4var levels were more frequently males, had a higher
creatinine level and a tendency towards higher NT-proBNP
levels. However, other clinical characteristics, including risk
factors, previous cardiac history, medical treatment, markers of
severity of heart failure and inflammation were comparable
between both groups.
Determinants of PF-4var levels in CAD patients
Significant correlations were noted between PF-4var levels and
age (r=20.15, p=0.03), creatinine (r=20.21, p=0.002), NT-
proBNP (r=20.21, p=0.003) and circulating platelet number
(r=0.233, p=0.001). Median levels of PF-4var were significantly
lower in men as compared to women (10 [7–15] ng/ml versus 14
[10–22] ng/ml, p,0.01). No significant correlations were noted
between PF-4var and sTNFRI, sTNFRII, number of circulating
white blood cells, lymphocytes, granulocytes or monocytes.
In multivariate regression analysis including age, gender,
creatinine, NT-proBNP and circulating platelet number, levels
of PF-4var were independently predicted by age (b=20.145,
p=0.028), gender (b=20.239, p=0.001), and circulating platelet
number (b=0.218, p,0.001).
Relationship between PF-4var levels and levels of PF-4
and RANTES in CAD patients
As shown in Table 1, levels of PF-4 and RANTES were
significantly lower in patients with lower PF-4var levels. A modest
but significant correlation was noted between PF-4var levels and
PF-4 (r=0.29, p=0.001) but not with RANTES (r=0.125,
p=0.074). In multivariate regression analysis including age,
gender, creatinine, NT-proBNP and circulating platelet number,
levels of PF-4 were independently predicted by gender (b=0.157,
p=0.024), and circulating platelet number (b=0.395, p,0.001).
Levels of RANTES were only determined by circulating platelet
number (b=0.165, p=0.023).







Age 68686 7 696 9 68 0.29
Gender (males) 172 (84%) 84 (79%) 89 (91%) 0.015
Previous AMI (%) 116 (57%) 60 (56%) 56 (57%) 0.89
Previous PCI (%) 71 (35%) 38 (36%) 33 (34%) 0.88
Previous CABG (%) 96 (47%) 47 (44%) 49 (50%) 0.40
Atrial fibrillation (%) 21 (10%) 10 (9%) 11 (11%) 0.82
Diabetes (%) 60 (30%) 35 (33%) 25 (26%) 0.28
Smoking (%) 22 (11%) 14 (13%) 8 (8%) 0.27
Hypertension (%) 131 (65%) 65 (62%) 66 (67%) 0.46
LVEF (%) 63696 3 696 4 69 0.26
NYHA II-III (%) 90 (44%) 45 (42%) 45 (46%) 0.74
6 minutes WD (m) 4286115 4226118 4346113 0.51
Creatinine (mg/dl) 160.22 0.9760.20 1.0660.24 0.004
NT-proBNP (pg/ml) 164 (79–354) 137 (69–291) 206 (100–415) 0.015
sTNFRI (pg/ml) 2.9961.15 2.9661.26 3.0361.02 0.67
sTNFRII (pg/ml) 8.6963.25 8.6763.63 8.7262.81 0.91
Medical treatment
Anti-platelets (%) 171 (84%) 90 (85%) 81 (82%) 0.94
Beta-blockers (%) 153 (75%) 75 (70%) 78 (80%) 0.15
ACE and/or ARB (%) 137 (67%) 73 (68%) 64 (65%) 0.41
Aldosterone antagonist (%) 14 (7%) 8 (8%) 6 (6%) 0.78
Coumarines (%) 36 (18%) 18 (17%) 18 (18%) 0.85
Statins (%) 133 (65%) 74 (69%) 59 (60%) 0.19
PF-4var (ng/ml) 10 (8–16) 15 (13–19) 7.5 (6–9) -
PF-4 (ng/ml) 3147 (2671–3772) 3260 (2919–3962) 2961 (2381–3493) 0.001
RANTES (pg/ml) 4044 (2405–6226) 4243 (2811–6687) 3662 (1913–6034) 0.028
Platelets 610
9 (/l) 228657 239658 215654 0.003
AMI indicates acute myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, LVEF left ventricular ejection fraction, NYHA
New York Heart Association, WD walking distance.
P values indicate a statistical significant difference between patients groups with PF-4var levels below and above the median value (10 ng/ml).
doi:10.1371/journal.pone.0031343.t001
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After a median follow-up of 2.5 years, 20 patients experienced
the primary outcome measure. In patients with events, levels of
NT-proBNP were higher than in patients without events (492
[267–1387] pg/ml versus 257 [76–292] pg/ml, p,0.001), where-
as levels of PF-4var were lower (8.5 [5.3–10] ng/ml versus 12 [8–
16] ng/ml, p=0.033). In contrast, levels of PF-4, RANTES and
platelet counts were similar in patients with and without events.
ROC analysis for events showed an area under the curve (AUC) of
0.82 (95% CI 0.73–0.90, p,0.001) for higher NT-proBNP levels
and an AUC of 0.32 (95% CI 0.19–0.45, p=0.009) for lower PF-
4var levels. No significant AUC was detected for PF-4, RANTES
or circulating platelets.
Figure 1 shows the Kaplan-Meier curves for patients (n=205)
with levels of NT-proBNP below and above the median value of
164 pg/ml (Figure 1A) and the Kaplan-Meier curves for patients
(n=205) with levels of PF-4var below and above the median value
of 10 ng/ml (Figure 1B).
The results of the Cox proportional hazards models are shown
in Table 2. Models 1 and 2, including clinical factors (age, gender,
creatinine, LVEF, medication) and either NT-proBNP or PF-4var,
showed an additional prognostic value of either NT-proBNP or
PF-4var. Model 3, including clinical factors and both NT-proBNP
and PF-4var, showed additional prognostic value of PF-4var on
top of NT-proBNP.
Figure 2 shows the Kaplan-Meier curves for patients with,
respectively, NT-proBNP levels and PF-4var levels below and
above the respective median values. The group of patients with
NT-proBNP levels above the median value and PF-4var levels
lower than the median value showed a significantly worse outcome
as compared to the other groups (p,0.001).
The secondary outcome measure (MACE or hospitalization for
congestive heart failure) was experienced by 40 patients. Figure 3
shows the Kaplan-Meier curves for patients with respectively NT-
proBNP levels and PF-4var levels below and above the respective
median values. Again, the group of patients with NT-proBNP
levels above the median value and PF-4var levels lower than the
median value showed a significantly worse outcome as compared
to the other groups (p,0.001). Table 3 shows the event rates per
patient year follow-up according to PF-4var and NT-proBNP
levels for the primary and secondary endpoint.
Discussion
In this study we show that low levels of PF-4var, a non-allelic
chemokine variant of PF-4, are associated with a worse outcome in
patients with stable CAD and preserved left ventricular function.
Moreover, PF-4var showed additional prognostic value on top of
NT-proBNP, a well validated prognostic parameter in CAD
patients. In contrast, levels of the other platelet-derived chemo-
kines, PF-4 and RANTES, were not associated with outcome.
Chemokines constitute a large family of chemotactic cytokines
which stimulate migration of various leucocyte subsets during
normal and pathological conditions [5–7]. PF-4var structurally
differs from PF-4 in only 3 amino acids. PF-4var and PF-4 are stored
in the a-granules of platelets, together with some other chemokines
suchasplatelet basicprotein (PBP/CXCL7) andRANTES.PF-4var
and PF-4 are released upon platelet activation by e.g. thrombin, a
much lower amount of PF-4var being secreted. PF-4var and PF-4
are inducible in monocytes stimulated by inflammatory mediators
[19]. Furthermore, PF-4var but not PF-4 is produced constitutively
by smooth muscle cells and by sarcoma cells after induction with
Figure 1. Kaplan-Meier curves for patients with levels of NT-proBNP lower and above the median value of 164 pg/ml (figure 1A)
and Kaplan-Meier curves for patients with levels of PF-4var lower and above the median value of 10 ng/ml (figure 1B).
doi:10.1371/journal.pone.0031343.g001
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regulated expression of these two PF-4 variants is different.
At high concentration (.1 mg/ml) PF-4 inhibits megakar-
y o p o i e s i sa n df u n c t i o n sa sn e g a t i v ea u t o c r i n er e g u l a t o rin vitro
[21] and in vivo [22]. Further, PF-4 has pro-thrombotic activity
by binding heparin, but it can also function as an anti-coagulant
via the generation of activated protein C [23]. However, in PF-4
knock-out mice, occlusive thrombi developed more slowly,
whereas PF-4 infusion restored thrombus formation, indicating
that this chemokine is rather pro-thrombotic [3]. In view of
the high concentrations required for these effects, it remains
to be seen whether PF-4var released into the circulation at
much lower concentrations is implicated in coagulation and
thrombogenesis.
Table 2. Multivariate analysis: hazard ratios for NT-proBNP and PF-4var.
Model Independent predictors Hazard ratio CI P-value
Model 1 Creatinine 9.95 1.18–84.23 0.038
(clinical+NT-proBNP) Beta-blockers 0.23 0.07–0.71 0.010
NT-proBNP 8.91 2.57–30.01 0.001
Model 2 Creatinine 18.3 12.7–98.6 0.001
(clinical+PF-4var) Beta-blockers 0.28 0.10–0.79 0.015
PF-4var 0.87 0.78–0.97 0.012
Model 3 Creatinine 9.24 1.03–83.12 0.047
(clinical+NT- Beta-blockers 0.22 0.07–0.70 0.011
proBNP+PF-4var) NT-proBNP 8.37 2.22–31.61 0.002
PF-4var 0.89 0.79–0.99 0.036
doi:10.1371/journal.pone.0031343.t002
Figure 2. Kaplan-Meier curves showing freedom from the primary outcome measure (death due to cardiovascular causes, non-fatal
myocardial infarction, non-fatal stroke or hospitalization for congestive heart failure) according to 4 groups: group 1: NT-proBNP
, median and PF-4var . median (n=64); group 2: NT-proBNP , median and PF-4var , median (n=42); group 3: NT-proBNP .
median and PF-4var . median (n=43); group 4: NT-proBNP . median and PF-4var , median (n=56).
doi:10.1371/journal.pone.0031343.g002
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fatal myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting or hospitalization for congestive
heart failure) according to 4 groups: group 1: NT-proBNP , median and PF-4var . median (n=64); group 2: NT-proBNP , median
and PF-4var , median (n=42); group 3: NT-proBNP . median and PF-4var . median (n=43); group 4: NT-proBNP . median and
PF-4var , median (n=56).
doi:10.1371/journal.pone.0031343.g003
Table 3. Event rates per patient year follow-up for the primary and secondary endpoint according to PF-4var and NT-proBNP
levels.
Primary endpoint Secondary endpoint
(death due to cardiovascular causes –non
fatal AMI- non fatal stroke-hospitalization
congestive heart failure)
(death due to cardiovascular causes – non















PF-4var . median and 64 79715 1 0.0045 74213 7 0.0344
NT-proBNP , median
PF-4var , median and 42 44907 1 0.0081 41500 4 0.0352
NT-proBNP , median
PF-4var . median and NT-proBNP .
median
43 46348 3 0.0236 43115 6 0.0508
PF-4var , median and NT-proBNP .
median
56 51919 15 0.1054 45481 23 0.1846
AMI indicates acute myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; FU, follow-up.
doi:10.1371/journal.pone.0031343.t003
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survival and differentiation into specific subtypes of macrophages
[24–26] and dendritic cells with altered cytokine producing
capacities [27]. However, PF-4 stimulates monocytes to induce
apoptosis in endothelial cells [28]. Although PF-4var is also not
chemotactic for monocytes, it does stimulate the migration of
immature dendritic cells, activated T cells and NK cells [13].
Despite its lower affinity for heparin, PF-4var is a more potent
inhibitor of endothelial cell growth and migration than PF-4, by
modulating the mitogenic activity of growth factors (e.g. basic
fibroblast growth factor) or antagonizing the chemotactic activity
of angiogenic chemokines (e.g. IL-8/CXCL8) [2]. The possible
mechanisms to explain the angiostatic effect of PF-4var include
interaction with CXCR3, displacement of growth factors for
binding to glycosaminoglycans, and direct interference with
angiogenic growth factors and chemokine heteromultimerization.
Although the formation of such chemokine heteromultimers [11]
inhibits endothelial cell growth, the disruption of the proinflam-
matory interaction between the platelet-derived chemokines PF-4
and RANTES also alters monocyte recruitment and inhibits
atherosclerosis [12]. Therefore, it needs to be investigated in depth
whether PF-4var, showing physico-chemical and biological
properties different from PF-4, can affect atherosclerosis and
why reduced levels of PF-4var are associated with a poor outcome
in CAD patients. Also, the reasons of lower PF-4var levels (e.g.
lower production or higher degradation of PF-4var) in CAD
patients with an adverse outcome need further study. Although
there is no mechanistic evidence about the involvement of PF-4var
in CAD, one may wonder whether low PF-4var blood levels could
reflect changes in an ongoing chemokine response. However, the
PF-4var levels did not correlate with those of the inflammatory
chemokine RANTES. Alternatively, it could be hypothesized that
the lowered PF-4var levels reflect the impact of blood platelet
counts on CAD. However, not only PF-4var, but also PF-4 and
RANTES levels correlated with the number of circulating
platelets, indicating that this correlation is not PF-4var specific.
Further, PF-4var but not PF-4 levels are associated with CAD
outcome, which is in line with the fact that both CXCR3 ligands
differ in biological potency as angiostatic factors and show
different affinity for glycosaminoglycans. In contrast to the
platelet-derived PF-4 and PF-4var, the other CXCR3 ligands
are not expected to occur at detectable levels in the blood
circulation of healthy persons. We verified the presence of
CXCL11/I-TAC in serum from both control (n=25) and CAD
patients (n=42), but found indeed that no CXCL11/I-TAC was
detectable (all levels remained below 80 pg/ml). Thus, it can be
concluded that the CXCR3 ligand PF-4var is a selective marker
for CAD.
Importantly, our results show that the prognostic value of PF-
4var is independent of NT-proBNP levels in stable CAD patients.
This indicates that low PF-4var levels affect outcome in a different
way as compared to neurohormonal activation. Indeed, unlike
NT-proBNP, no significant PF-4var gene expression has been
detected in heart and brain (NCBI Gene Expression Omnibus
database). However, the NT-proBNP receptor NPR-A is most
abundantly expressed in large blood vessels, and endothelial cells
are the major target cells for angiostatic PF-4var via binding to
CXCR3. Of note, no correlation was found between PF-4var
levels and markers of inflammation such as sTNFRI and sTNFRII
or the number of circulating white blood cells, lymphocytes,
granulocytes or monocytes. This is in contrast with the well known
relationship between NT-proBNP levels and different inflamma-
tory markers including high-sensitive C-reactive protein [29].
Remarkably, patients who presented with both low PF-4var levels
and high NT-proBNP levels, had a clear adverse outcome as
compared to the other groups. This was not only noted for the
primary outcome measurement, but even more for the secondary
outcome measurement which included revascularization during
follow-up. These observations implicate that an approach with two
different biomarkers, probably representing distinct pathophysio-
logical pathways (one evaluating cardiovascular function and
remodeling and one evaluating platelet function) may be relevant
for risk stratification of patients with stable CAD. A recent paper
by Schnabel et al. [30] looked at a multiple marker approach to
risk stratification in a large population of patients with stable CAD.
Although the different markers (reflecting inflammation, lipid
metabolism, renal function and cardiovascular function and
remodeling) offered incremental predictive ability over established
risk factors, combination of the single markers did not enhance risk
prediction from a clinical perspective. Markers of platelet function
and activation were however not included in that study. Also, the
clear prognostic impact of low PF-4var levels may be further
evaluated as potential parameter for new anti-platelet drug
therapies in patients with stable CAD.
In conclusion, low levels of the chemokine PF-4var, a non-allelic
variant of PF-4, are associated with a poor outcome in patients
with stable CAD. The prognostic value of PF-4var is independent
of the prognostic value of NT-proBNP, a well validated prognostic
marker in these patients. These results warrant further studies
regarding the pathophysiological function of PF-4var and its
potential role as marker of platelet-related activation in patients
with stable CAD.
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